Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNMT | O43148 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 2/20 | 0.35 |
| ▸ | AHCY | P23526 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18631627 | 0.87 | NNMT (0.34) | ADORA3TRPM2NNMT | |
| SCHEMBL18630484 | 0.81 | UBA6 (0.36) | ADORA3AHCY | |
| SCHEMBL1794227 | 0.79 | NAE1 (0.54) | RNMTTRPM2 | |
| SCHEMBL18630476 | 0.78 | DNPH1 (0.49) | TRPM2AHCY | |
| SCHEMBL18631613 | 0.76 | ATG7 (0.44) | ADORA3AHCY | |
| SCHEMBL18630436 | 0.74 | UBA6 (0.40) | TRPM2AHCY | |
| SCHEMBL18630543 | 0.73 | SLC29A1 (0.41) | NNMT | |
| SCHEMBL18630414 | 0.72 | NNMT (0.40) | ADORA3NNMTAHCY | |
| SCHEMBL23080201 | 0.72 | PAX8 (0.47) | ADORA3 | |
| SCHEMBL18630399 | 0.72 | ADORA2B (0.46) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | RNMT 1365/4885ABL1 2724/4885ADORA3 1669/4885 |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | RNMT 1365/4885ABL1 2724/4885ADORA3 1669/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | RNMT 2744/4885ABL1 2833/4885ADORA3 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.